PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.76
Negative P/E while RVPH shows 24.14. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
5.04
P/B of 5.04 while RVPH has zero book value. Bruce Berkowitz would examine asset quality advantage.
-10.33
Negative FCF while RVPH shows P/FCF of 96.56. Joel Greenblatt would examine cash flow improvement potential.
-10.35
Negative operating cash flow while RVPH shows P/OCF of 96.56. Joel Greenblatt would examine operational improvement potential.
5.04
Fair value ratio of 5.04 while RVPH has zero value. Bruce Berkowitz would examine valuation methodology.
-14.24%
Negative earnings while RVPH shows yield of 1.04%. Joel Greenblatt would examine path to profitability.
-9.68%
Negative FCF while RVPH shows yield of 1.04%. Joel Greenblatt would examine cash flow improvement potential.